| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progre...
Blog Post - OBIO | AVIM therapy: Durability, Reversibility, and Reproducibility of Effect September 22, 2025 September 22, 2025...
Results from long-term follow up of patients treated with atrioventricular interval modulation ("AVIM") therapy show bl...
HC Wainwright & Co. analyst Yi Chen maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and lowers the price targe...
BTIG analyst Marie Thibault downgrades Orchestra BioMed Hldgs (NASDAQ:OBIO) from Buy to Neutral.